200,000+ products from a single source!
sales@angenechem.com
CAS No: 274-56-6 Catalog No: AG003841 MDL No:MFCD08752622
Title | Journal |
---|---|
Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones. | Bioorganic & medicinal chemistry letters 20120915 |
Au(I)-catalyzed and iodine-mediated cyclization of enynylpyrazoles to provide pyrazolo[1,5-a]pyridines. | Organic & biomolecular chemistry 20120907 |
Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: potent and orally active antagonists of corticotropin-releasing factor 1 receptor. | Journal of medicinal chemistry 20120614 |
Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity. | Bioorganic & medicinal chemistry 20120301 |
Ultrasound assisted one-pot, three-components synthesis of pyrimido[1,2-a]benzimidazoles and pyrazolo[3,4-b]pyridines: A new access via phenylsulfone synthon. | Ultrasonics sonochemistry 20120101 |
Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors. | Bioorganic & medicinal chemistry 20120101 |
Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR. | Bioorganic & medicinal chemistry 20120101 |
Synthesis, X-ray crystal structure and fluorescent spectra of novel pyrazolo[1,5-a]pyrazin-4(5H)-one derivatives. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20111015 |
Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity. | Bioorganic & medicinal chemistry letters 20110915 |
A copper-mediated cyclization reaction of hydrazine with enediynones providing pyrazolo[1,5-a]pyridines. | Organic & biomolecular chemistry 20110207 |
One-step synthesis of diarylpyrazolo[3,4-b]pyridines from isoflavones. | Journal of combinatorial chemistry 20100712 |
Ethyl 3-{5-[(diethyl-amino)meth-yl]isoxazol-3-yl}-2-phenyl-pyrazolo[1,5-a]pyridine-5-carboxyl-ate. | Acta crystallographica. Section E, Structure reports online 20100401 |
Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies. | European journal of medicinal chemistry 20100101 |
The first examples of chemical modification of oligomycin A. | The Journal of antibiotics 20100101 |
Novel pyrazolopyrimidines as highly potent B-Raf inhibitors. | Bioorganic & medicinal chemistry letters 20091215 |
An efficient one-step synthesis of heterobiaryl pyrazolo[3,4-b]pyridines via indole ring opening. | Organic letters 20091119 |
Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. | Bioorganic & medicinal chemistry letters 20091101 |
Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors. | Journal of medicinal chemistry 20090326 |
The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors. | Bioorganic & medicinal chemistry letters 20081015 |
Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. | Bioorganic & medicinal chemistry letters 20080801 |
Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model. | ChemMedChem 20080601 |
Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems. | Journal of medicinal chemistry 20080410 |
Synthesis, radiofluorination, and in vitro evaluation of pyrazolo[1,5-a]pyridine-based dopamine D4 receptor ligands: discovery of an inverse agonist radioligand for PET. | Journal of medicinal chemistry 20080327 |
Concise routes to pyrazolo[1,5-a]pyridin-3-yl pyridazin-3-ones. | Organic & biomolecular chemistry 20080107 |
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2. | Bioorganic & medicinal chemistry letters 20071115 |
Rapid hit to lead evaluation of pyrazolo[3,4-d]pyrimidin-4-one as selective and orally bioavailable mGluR1 antagonists. | Bioorganic & medicinal chemistry letters 20070801 |
Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents. | Bioorganic & medicinal chemistry letters 20070801 |
Pyrazolo[1,5-a]pyridine antiherpetics: effects of the C3 substituent on antiviral activity. | Bioorganic & medicinal chemistry letters 20070515 |
Synthesis of C-6 substituted pyrazolo[1,5-a]pyridines with potent activity against herpesviruses. | Bioorganic & medicinal chemistry 20060215 |
Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity. | Bioorganic & medicinal chemistry letters 20060115 |
Tissue distribution of radioiodinated FAUC113: assessment of a pyrazolo(1,5-a) pyridine based dopamine D4 receptor radioligand candidate. | Nuklearmedizin. Nuclear medicine 20060101 |
Synthesis of novel substituted 2-phenylpyrazolopyridines with potent activity against herpesviruses. | Bioorganic & medicinal chemistry 20050915 |
New pyrazolo[3,4-b]pyridones as selective A(1) adenosine receptor antagonists: synthesis, biological evaluation and molecular modelling studies. | Organic & biomolecular chemistry 20050621 |
Pyrazolopyridine antiherpetics: SAR of C2' and C7 amine substituents. | Bioorganic & medicinal chemistry 20050401 |
Synthesis and biological evaluation of some acyclic 4,6-disubstituted 1H-pyrazolo[3,4-d]pyrimidine nucleosides. | Nucleosides, nucleotides & nucleic acids 20030101 |
Di- and trisubstituted pyrazolo[1,5-a]pyridine derivatives: synthesis, dopamine receptor binding and ligand efficacy. | Bioorganic & medicinal chemistry letters 20020225 |
© 2019 Angene International Limited. All rights Reserved.